

Immuno**SEP**



Under the auspices



ΕΛΛΗΝΙΚΗ ΕΤΑΙΡΕΙΑ ΧΗΜΕΙΟΘΕΡΑΠΕΙΑΣ
HELLENIC SOCIETY OF CHEMOTHERAPY



International Symposium on Immunotherapy of Severe Infections

**16-17 May 2024, Kalamata / Greece
Elite Congress Centre**

Conference Programme



ImmunoSep, HAP2, HDM-FUN projects have received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847422 (ImmunoSep), 847782 (HAP2), 847507 (HDM-FUN).



Welcome note,

It is with great joy that we welcome you to Kalamata, Greece for the “International Symposium on Immunotherapy of Severe Infections”. Immunotherapy of infections is a rapidly evolving topic which became very attractive during the pandemic following the approvals of anakinra, dexamethasone and tocilizumab for severe COVID-19 pneumonia. These approvals generated the belief that immunotherapy may also become treatment for severe infections other than COVID-19.

None of the organizers are considering ourselves as experts. However, we consider ourselves as pioneers who, after receiving funding from the European Union, are putting our efforts together trying to change the traditional way of sepsis management. This is why this Conference is carrying the logos of three major consortia who brought novelty in sepsis management:

- **ImmunoSep**, co-ordinated by Prof. Mihai G. Netea, which studied the precision treatment of macrophage activation-like syndrome and sepsis-induced immunoparalysis with anakinra and recombinant human interferon-gamma respectively;
- **HAP2**, co-ordinated by Prof. Antoine Roquilly, which studied the intervention with recombinant human interferon-gamma and dexamethasone in patients with severe hospital-acquired pneumonia; and
- **HDM-FUN-Candidemia**, co-ordinated by Prof. Frank van de Veerdonk, which studied the intervention with recombinant human interferon-gamma in patients with severe candidemia.

We hope that this symposium achieves to generate tight bonds of collaboration among clinicians and scientists in Europe, so that research in the field is promoted towards improvement of patients' care.


May 2024,

Mihai G. Netea

Radboud University Nijmegen
the Netherlands

Evangelos J. Giamarellos-Bourboulis

National and Kapodistrian University of Athens,
Greece



DAY 1, 16 May 2024

9.00 – 9.15 Welcome Mihai Netea and Evangelos J. Giamarellos-Bourboulis

Immune therapy for hospital-acquired infections

Chair: Maria Ntaganou (Athens, GR), W. Joost Wiersinga (Amsterdam, NL)

9.15 – 9.45 *Metabolomic adaptation to systemic inflammation*

Jeremie Poschmann, Nantes University, France

9.45 – 10.15 *Epidemiology and outcomes of hospital-acquired pneumonia*

Despoina Koulenti, University of Athens, Greece

10.15 – 10.45 *Towards new guidelines for the treatment of pneumonia*

Antoni Torres, University of Barcelona, Spain

10.45 – 11.00 Small talk: *Butyrate-producing bacteria protect against pneumonia*

Bob Kullberg, Amsterdam UMC

11.00 – 11.30 Break

11.30 – 12.00 *Immune regulation in sepsis: pioneering progress on a daunting path*

Thierry Calandra, Centre Hospitalier Universitaire Vaudois, Switzerland

12.00 – 12.30 *IL-1Ra treatment in COVID-19*

Mihaela Lupse, UMF Cluj-Napoca, Romania

12.30 – 13.30 Light Buffet Lunch and Poster Session

Immune dysregulation in severe infections

Chair: Elisabeth Paramythiotou (Athens, GR),

Pavlos Myrianthefs (Athens, GR)

13.30 – 14.00 *Systemic inflammation and resistance in infections*

Irit Gat-Viks, Tel Aviv University, Israel



DAY 1, 16 May 2024

- 14.00 – 14.15 Small talk : *A novel sepsis endotype*
Christos Psarrakis, Athens
- 14.15 – 14.30 Small talk: *A persistent infection with COVID-19*
Magda Vergouwe, Amsterdam UMC
- 14.30 – 15.00 *Immune dysregulation in COVID-19*
Antigone Kotsaki, Hellenic Institute for the Study of Sepsis, Greece
- 15.00 – 15.30 *Personalized Immunotherapy in fungal infections*
Frank van de Veerdonk, Radboud University Medical Center, The Netherlands
- 15.30 – 16.00 Coffee Break
- 16.00 – 16.30 *Microbiome modulation in pneumonia*
Antoine Roquilly, Nantes University, France
- 16.30 – 17.00 *Complement inhibition in sepsis*
Alexander Vlaar, Academic Medical Center, The Netherlands

Keynote lecture

Chair: Evangelos J. Giamarellos-Bourboulis (Athens, GR)

- 17.00 – 17.30 *What have we learned about immune therapy for respiratory diseases?*
Michael Niederman, Cornell University, USA
- 19.00 Get Together



DAY 2, 17 May 2024

Immune mechanisms and immunotherapy in severe fungal infections **Chair: George Dimopoulos (Athens, GR), Irene Christaki (Ioannina, GR)**

- 9.00 – 09.30 *Not all hosts are the same*
Oliver Kurzai, University of Wuerzburg, Germany
- 9.30 – 10.00 *From genetics to mechanisms in aspergillosis*
Melisa Johnson, Duke University, USA
- 10.00 – 10.15 *Small talk: Host response heterogeneity in sepsis transcriptome*
JM Butler, Amsterdam UMC
- 10.15 – 10.30 *Small talk: Blood metabolome in critically ill patients*
Melanie Petrier, Inserm
- 10.30 – 11.00 **Coffee Break**
- 11.00 – 11.30 *Biology of the phagosome in severe fungal infection*
George Chamilos, University of Crete, Greece
- 11.30 – 11.45 *Small talk: Soluble cytokine receptors in sepsis*
Athanasios Ziogas, Radboud UMC, Nijmegen
- 11.45 – 12.00 *Small talk: Syndecan-1 as a marker of glycocalyx injury*
Hui Wang, Amsterdam UMC
- 12.00 – 12.30 *Viral associated pulmonary aspergillosis*
Joost Wauters, University Hospital Leuven, Belgium
- 12.30 – 13.30 **Light Buffet Lunch**

Immune therapy in sepsis

Chair: Tom van der Poll (Amsterdam, NL), Antoine Roquilly (Nantes, FR)

- 13.30 – 14.00 *The ImmunoSep trial*
Evangelos J. Giamarellos-Bourboulis, National and Kapodistrian University of Athens, Greece
- 14.00 – 14.15 *Small talk: A dysregulated immune profile score in sepsis*
Erik Michels, Amsterdam, UMC
- 14.15 – 14.45 *Disease tolerance: the clinical perspective*
Sebastian Weis, Jena University Hospital, Germany
- 14.45 – 15.15 *Epigenetic regulation of myeloid cell function in infections*
Mihai Netea, Radboud University Medical Center, The Netherlands
- 15.15 **Words of good bye**



CHAIRMEN- INVITED SPEAKERS

Joe M Butler, (*Amsterdam UMC, The Netherlands*)

Thierry Calandra, (*Vaudois, Switzerland*)

George Chamilos, (*Crete, Greece*)

Evangelos J. Giamarellos-Bourboulis, (*Athens, Greece*)

Irene Christaki, (*Ioannina, Greece*)

Irit Gat-Viks, (*Tel Aviv, Israel*)

Melisa Johnson, (*Duke University, USA*)

Bob Kullberg, (*Amsterdam UMC, The Netherlands*)

Despoina Koulenti, (*Athens, Greece*)

Antigone Kotsaki, (*Athens, Greece*)

Oliver Kurzai, (*University of Wuerzburg, Germany*)

Michaela Lupse, (*UMF Cluj-Napoca, Romania*)

Erik Michels, (*Amsterdam UMC, The Netherlands*)

Pavlos Myrianthefs, (*Athens, Greece*)

Mihai Netea, (*Nijmegen, The Netherlands*)

Michael Niederman, (*New York, USA*)

Maria Ntaganou, (*Athens, Greece*)

Elisabeth Paramythiotou, (*Athens, Greece*)

Melanie Petrier, (*Nantes, France*)

Tom van der Poll, (*Amsterdam, The Netherlands*)

Jeremie Poschmann, (*Nantes, France*)

Christos Psarrakis, (*Athens, Greece*)

Antoine Roquilly, (*Nantes, France*)

Antoni Torres, (*Barcelona, Spain*)

Frank van de Veerdonk, (*Nijmegen, The Netherlands*)

Magda Vergouwe, (*Amsterdam UMC, The Netherlands*)

Alexander Vlaar, (*Amsterdam, The Netherlands*)

Hui Wang, (*Amsterdam UMC, The Netherlands*)

Joost Wauters, (*Leuven, Belgium*)

Sebastian Weis, (*Jena, Germany*)

W. Joost Wiersinga, (*Amsterdam, The Netherlands*)

Athanasios Ziogas, (*Radboud UMC, Nijmegen*)



USEFUL INFORMATION

Venue:

Elite City Resort Kalamata
237 Navarinou Str., 241 00 Kalamata, Greece

Registration Fees: € 250,00

With this all-inclusive registration, you gain entry to a dynamic lineup of sessions on 16 & 17 May 2024. Access to the exhibition area, poster area, coffee breaks, light lunches and meeting package. VAT 24% – Included in price.

CME: The International Symposium on Immunotherapy of Severe Infections has been accredited by the Panhellenic Medical Association (PHMA) with 10,5 ECMECs.

Certificate: Meeting Certificate will be sent with a minimum attendance of 60% of the congress time to all participants by e mail.

Congress Organizer



IMAGINE CONGRESS & TRAVEL
9, kolokotroni str., 105 62 Athens - Greece
Phone: +30 210 3252520
v.antonopoulou@imaginecongress.gr
www.imaginecongress.gr



The organizers of the International Symposium on Immunotherapy of Severe Infections wish to express their gratitude to our supporters

ELPEN



Hellenic Institute for the Study of Sepsis



ΕΛΛΗΝΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΜΕΛΕΤΗΣ ΤΗΣ ΣΗΨΗΣ
HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS

Menarini Hellas



MENARINI HELLAS A.E.

ImmunoSep (Horizon 2020 grant 847422)

immuno**SEP**

Radboud UMC

Radboudumc
university medical center

Sobi AB (publ)



Uni-Pharma, Kleon-Tsetis



ImmunoSep, HAP2, HDM-FUN projects have received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847422 (ImmunoSep), 847782 (HAP2), 847507 (HDM-FUN).

NOTES

A series of horizontal dotted lines for taking notes, spanning the width of the page.



NOTES

A series of horizontal dotted lines for writing notes, spanning the width of the page.



Lacto Levure®



No 1 προβιοτικό
στην Ελλάδα*
*NOVA HELLAS
OTC MARKET 06/2018



Νέα προοπτική

Συμπλήρωμα διατροφής για την **προστασία**
και την **αποκατάσταση** της **εντερικής χλωρίδας**

✓ **4 προβιοτικά - 5,5 δισ.** ζωντανά κύτταρα


Saccharomyces boulardii • Bifidobacterium lactis • Lactobacillus acidophilus • Lactobacillus plantarum

1 κάψουλα την ημέρα

Να μη γίνεται υπέρβαση της συνιστώμενης ημερήσιας δόσης • Τα συμπληρώματα διατροφής δεν πρέπει να χρησιμοποιούνται ως υποκατάστατο μιας ισορροπημένης διαίτης • Το προϊόν αυτό δεν προορίζεται για την πρόληψη, αγωγή ή θεραπεία ανθρώπινης νόσου. Συμβουλευτείτε το γιατρό σας αν είστε έγκυος, θηλάζετε, βρίσκεστε υπό φαρμακευτική αγωγή ή αντιμετωπίζετε προβλήματα υγείας • Να φυλάσσεται μακριά από τα μικρά παιδιά • Αρ. Γνωστοποίησης ΕΟΦ: 89375/16-12-2011 (ο αριθμός γνωστοποίησης στον ΕΟΦ δεν επεξηγεί θέση άδειας κυκλοφορίας από τον ΕΟΦ)



Pharmaceutical Laboratories S.A.



Fomicyt[®]

fosfomicin i.v.



FOM/FFA/11-2019/02

From magic bullets to
Smart Bullets^{*}

* Valent P, J Innate Immun 2016;8:111-120

